Welcome to our dedicated page for SRRA news (Ticker: SRRA), a resource for investors and traders seeking the latest updates and insights on SRRA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SRRA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SRRA's position in the market.
Sierra Oncology (NASDAQ: SRRA) announced a term loan agreement with Oxford Finance for up to
Sierra Oncology, Inc. (NASDAQ: SRRA) announced positive topline results from the Phase 3 MOMENTUM study for momelotinib (MMB) in myelofibrosis patients who are symptomatic and anemic. The trial met all primary and key secondary endpoints, showing a 25% TSS reduction in the MMB group compared to 9% in the control (p=0.0095) and 31% transfusion independence vs. 20% (p=0.0064). The full dataset will be presented at an upcoming medical meeting, with a New Drug Application planned for Q2 2022.
Sierra Oncology (NASDAQ: SRRA) has published a review article in the Journal of Hematology & Oncology, highlighting the potential of momelotinib as a novel treatment for anemia in myelofibrosis patients. This article emphasizes momelotinib's ability to meet a critical unmet need in treating anemia associated with myelofibrosis, a condition affecting 40-90% of patients. The company anticipates topline data from the Phase 3 MOMENTUM study by January 2022, with an NDA filing planned for Q2 2022 if results are favorable.
Sierra Oncology (NASDAQ: SRRA) has expedited the timeline for the topline data readout of its pivotal Phase 3 MOMENTUM trial for momelotinib, now expected by the end of January 2022. This study targets patients with myelofibrosis, particularly those with anemia. If results are favorable, the company plans to file a New Drug Application (NDA) with the FDA in Q2 2022. CEO Stephen Dilly expressed enthusiasm about the data timeline and its potential impact on treatment options for myelofibrosis patients.
Sierra Oncology (SRRA), a biopharmaceutical firm focusing on rare cancers, has granted stock options to nine new employees under its 2018 Equity Inducement Plan. In total, 64,800 options to purchase shares at $21.55 each have been issued. The options vest 25% on the first anniversary of employment, with the remaining 75% vesting over 36 months, contingent on continued employment. This strategy aims to attract talent while aligning employee interests with shareholder value.
Sierra Oncology, Inc. (NASDAQ: SRRA) has announced its participation in the virtual 2022 HC Wainwright BioConnect Conference from January 10-13, 2022. CEO Stephen Dilly will present an overview of the company, available on demand starting at 7:00 am ET on January 10. A replay will be accessible for 90 days via the Investors section of Sierra's website. Sierra focuses on delivering targeted therapies for rare cancers, leveraging scientific expertise to transform cancer treatment paradigms.
Sierra Oncology, Inc. (NASDAQ: SRRA) presented new data from retrospective analyses of Phase 3 SIMPLIFY studies at the 63rd ASH Annual Meeting, showing baseline ferritin predicts Week 24 Transfusion Independence Response for momelotinib and ruxolitinib in myelofibrosis patients. Key findings reveal that momelotinib shows a superior response over ruxolitinib, especially in patients with ferritin levels between 90-650 ng/mL. The company awaits the topline results from the MOMENTUM clinical trial, expected by February 2022, and plans to file a New Drug Application with the FDA.
Sierra Oncology (NASDAQ: SRRA) announced an analyst and investor event scheduled for December 16, 2021, focusing on the treatment of anemia in myelofibrosis patients. Dr. Prithviraj Bose from MD Anderson Cancer Center will present data from the Phase 3 SIMPLIFY studies on momelotinib, a drug under investigation for myelofibrosis. The company awaits topline results from the MOMENTUM trial, expected by February 2022, and plans to submit a New Drug Application to the FDA in Q2 2022, pending positive results.
Sierra Oncology, Inc. (SRRA), a biopharmaceutical firm, has granted stock options to six new employees under its 2018 Equity Inducement Plan. In total, options to purchase 39,000 shares were issued, each with an exercise price of $23.28, equal to the stock's closing price on the grant date. The options vest 25% on the first anniversary and the remaining 75% in 36 monthly installments, contingent upon continued employment. This move aims to incentivize new talent contributing to Sierra's mission in targeted cancer therapies.
Sierra Oncology, Inc. (NASDAQ: SRRA), a biopharmaceutical company focused on targeted therapies for rare cancers, will participate in the 2021 Jefferies London Healthcare Conference. CEO Stephen Dilly will present an overview of the company on November 18, 2021, at 8:00 am GMT (3:00 am ET). The presentation will be available on demand for conference attendees and can be accessed later on the company's website, with replays available for about 30 days.
FAQ
What is the market cap of SRRA (SRRA)?
